Eli Lilly (LLY) reported quarterly earnings of $8.55 per share on May 5, 2026, surpassing the Zacks Consensus Estimate of $7.06 per share, and significantly increasing from $3.34 per share a year ago. The company also posted revenues of $19.8 billion for the quarter, beating forecasts by 12.37% and up from $12.73 billion in the same quarter last year. This marks the fourth consecutive quarter where Eli Lilly has exceeded consensus EPS and revenue estimates.
The earnings surprise for this quarter was +21.06%. Despite strong earnings, Lilly’s shares have declined about 20.8% since the start of the year, compared to a 4.2% gain in the S&P 500. The current consensus EPS estimate for the upcoming quarter is $8.43 on revenues of $19.87 billion, and for the fiscal year, the estimates are $33.50 on $81.95 billion in revenue.
Pfizer (PFE), a peer in the same industry, is scheduled to release its quarterly results on May 5, 2026, with expected earnings of $0.74 per share, reflecting a year-over-year decrease of 19.6% and projected revenues of $13.82 billion, a slight increase of 0.8% from the previous year.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
